New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
